Drug-Induced Hepatotoxicity or Drug-Induced Liver Injury

Clinics in Liver Disease

Volumn 13, Issue 2, 2009, Pages 277-294

  Pugh, Aaron J ^a   Barve, Ashutosh J ^a   Falkner, Keith ^a   Patel, Mihir ^a   McClain, Craig J ^a,b  

^a University of Louisville School of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alternative medicine; Antibiotics; Antiretroviral; Drugs; Liver injury

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; BETA LACTAM; DIDANOSINE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; MONOAMINE OXIDASE INHIBITOR; NEVIRAPINE; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PARACETAMOL; PRAVASTATIN; PSYCHOTROPIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RALOXIFENE; RITONAVIR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; STAVUDINE; TETRACYCLINE; TIPRANAVIR; TOLCAPONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ACUTE HEPATITIS; AMINOTRANSFERASE BLOOD LEVEL; CHOLESTASIS; CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG FORMULATION; DRUG METABOLISM; DRUG WITHDRAWAL; EOSINOPHILIA; FATTY LIVER; GASTROINTESTINAL SYMPTOM; GRANULOMATOSIS; HEPATITIS; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERSENSITIVITY; HYPERTRIGLYCERIDEMIA; LACTIC ACIDOSIS; LIVER FAILURE; LIVER FUNCTION TEST; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; PARKINSON DISEASE; PORTAL HYPERTENSION; REVIEW; SIDE EFFECT; SKIN ALLERGY; STEATOSIS; STEVENS JOHNSON SYNDROME; SYMPTOM; UNITED STATES;

ANTI-INFECTIVE AGENTS; ANTI-RETROVIRAL AGENTS; COMPLEMENTARY THERAPIES; HUMANS; LIVER; LIVER FAILURE, ACUTE; PSYCHOTROPIC DRUGS;

EID: 65549148947     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2009.02.008     Document Type: Review

References (137)

1. Lee W.M. Drug-induced hepatotoxicity. N Engl J Med 349 5 (2003) 474-485
2. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36 2 (2002) 451-455
3. Nathwani R.A., and Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis 10 2 (2006) 207-217 vii
4. Chang C.Y., and Schiano T.D. Review article: drug hepatotoxicity. Aliment Pharmacol Ther 25 10 (2007) 1135-1151
5. Fontana R.J. Acute liver failure including acetaminophen overdose. Med Clin North Am 92 4 (2008) 761-794 viii
6. Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med 352 21 (2005) 2211-2221
7. Gunawan B.K., and Kaplowitz N. Mechanisms of drug-induced liver disease. Clin Liver Dis 11 3 (2007) 459-475 v
8. Sotaniemi E.A., Arranto A.J., Pelkonen O., et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 61 3 (1997) 331-339
9. Maddrey W.C. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol 39 4 Suppl 2 (2005) S83-S89
10. Castell J.V., and Castell M. Allergic hepatitis induced by drugs. Curr Opin Allergy Clin Immunol 6 4 (2006) 258-265
11. Lewis J.H. Medication-related and other forms of toxic liver injury. In: Brandt L.J. (Ed). Clinical practice of gastroenterology (1998), Churchill Livingstone, Philadelphia 855
12. Lee W.M. Drug-induced hepatotoxicity. N Engl J Med 333 17 (1995) 1118-1127
13. Lee W.M., and Seremba E. Etiologies of acute liver failure. Curr Opin Crit Care 14 2 (2008) 198-201
14. Toth P.P., and Davidson M.H. High-dose statin therapy: benefits and safety in aggressive lipid lowering. J Fam Pract 57 5 Suppl High-Dose (2008) S29-S36
15. Bhardwaj S.S., and Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis 11 3 (2007) 597-613 vii
16. Cohen D.E., Anania F.A., and Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 97 8A (2006) 77C-81C
17. Anfossi G., Massucco P., Bonomo K., et al. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr Metab Cardiovasc Dis 14 4 (2004) 215-224
18. Marino G., and Lewis J.H. Drug-induced liver disease. Curr Opin Gastroenterol 17 3 (2001) 232-241
19. Bristol-Myers Squibb. Product information. Pravachol [pravastatin] (2007), Bristol-Myers Squibb Company, Princeton (NJ)
20. Tolman K.G. Defining patient risks from expanded preventive therapies. Am J Cardiol 85 12A (2000) 15E-19E
21. Merck/Schering-Plough. Product information. Zetia [Ezetimibe] (2007), Merck/Schering-Plough Pharmaceuticals, North Wales (PA)
22. Tuteja S., Pyrsopoulos N.T., Wolowich W.R., et al. Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation. Pharmacotherapy 28 9 (2008) 1188-1193
23. Pieper J.A. Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am J Health Syst Pharm 60 13 Suppl 2 (2003) S9-14 quiz S25
24. McCormack P.L., and Keating G.M. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 65 18 (2005) 2719-2740
25. Dalton T.A., and Berry R.S. Hepatotoxicity associated with sustained-release niacin. Am J Med 93 1 (1992) 102-104
26. Madariaga M.G. Drug-related hepatotoxicity. N Engl J Med 354 20 (2006) 2191-2193 [author reply 2191-3]
27. Patel S.D., and Taylor H.C. Intrahepatic cholestasis during nicotinic acid therapy. Cleve Clin J Med 61 1 (1994) 70-75 quiz 80-2
28. Clementz G.L., and Holmes A.W. Nicotinic acid-induced fulminant hepatic failure. J Clin Gastroenterol 9 5 (1987) 582-584
29. Mullin G.E., Greenson J.K., and Mitchell M.C. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med 111 3 (1989) 253-255
30. Hodis H.N. Acute hepatic failure associated with the use of low-dose sustained-release niacin. JAMA 264 2 (1990) 181
31. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 164 7 (2004) 697-705
32. McKenney J.M., Proctor J.D., Harris S., et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 271 9 (1994) 672-677
33. Lucena M.I., Andrade R.J., Vicioso L., et al. Prolonged cholestasis after raloxifene and fenofibrate interaction: a case report. World J Gastroenterol 12 32 (2006) 5244-5246
34. de Diego Lorenzo A., Catalina V., Garcia Sanchez A., et al. [Cholestatic hepatitis caused by gemfibrozil]. Rev Esp Enferm Dig 93 9 (2001) 610-611
35. Graham D.J., Green L., Senior J.R., et al. Troglitazone-induced liver failure: a case study. Am J Med 114 (2003) 299-306
36. Chan K.A., Truman A., Gurwitz J.H., et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med 163 6 (2003) 728-734
37. Marcy T.R., Britton M.L., and Blevins S.M. Second-generation thiazolidinediones and hepatotoxicity. Ann Pharmacother 38 (2004) 1419-1423
38. Forman L.M., Simmons D.A., and Diamond R.H. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 132 2 (2000) 118-121
39. Al-Salman J., Arjomand H., Kemp D.G., et al. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 132 (2000) 121-124
40. Farley-Hills E., Sivasankar R., and Martin M. Fatal liver failure associated with pioglitazone. BMJ 329 7463 (2004) 429
41. Chase M.P., and Yarze J.C. Pioglitazone-associated fulminant hepatic failure. Am J Gastroenterol 97 (2002) 502-503
42. GlaxoSmithKline. Product information: Avandia [Rosiglitazone] (April 2007), GlaxoSmithKline, Research Triangle Park (NC)
43. Takeda Pharmaceuticals. Product information: Actos [Pioglitazone] (August 2007), Takeda Pharmaceuticals America, Inc, Deerfield (IL)
44. DeSanty K.P. Antidepressant-induced liver injury. Ann Pharmacother 41 7 (2007) 1201-1211
45. GlaxoSmithKline. Product information: Paxil [paroxetine] (January 2008), GlaxoSmithKline, Research Triangle Park (NC)
46. Bristol-Myers Squibb. Product information: Serzone [Nefazodone] (October 2003), Bristol-Myers Squibb Company, Princeton (NJ)
47. Watkins P. COMT inhibitors and liver toxicity. Neurology 55 11 (2000) S51-S52
48. Lew M.F., and Kricorian G. Results from a 2-year centralized tolcapone liver enzyme monitoring program. Clin Neuropharmacol 30 (2007) 281-286
49. Valeant Pharmaceuticals. Product information: Tasmar [Tolcapone] (December 2006), Valeant Pharmaceuticals International, Costa Mesa (CA)
50. Temesgen Z., and Wright A.J. Antiretrovirals. Mayo Clin Proc 74 12 (1999) 1284-1301
51. Vogel M., and Rockstroh J.K. Hepatotoxicity and liver disease in the context of HIV therapy. Curr Opin HIV AIDS 2 4 (2007) 306-313
52. Sulkowski M.S., Thomas D.L., Chaisson R.E., et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283 1 (2000) 74-80
53. Nuňez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 44 Suppl 1 (2006) S132-S139
54. Nuňez M., and Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf 28 1 (2005) 53-66
55. Johnson A., Ray A., Hanes J., et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 276 (2001) 40847-40857
56. Parker R.A., Flint O.P., Mulvey R., et al. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteosome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol 67 6 (2005) 1909-1919
57. Cooper C.L. HIV antiretroviral medications and hepatotoxicity. Curr Opin HIV AIDS 2 6 (2007) 466-473
58. Lai K.K., Gang D.L., Zawacki J.K., et al. Fulminant hepatic failure associated with 2′, 3′-dideoxyinosine (ddI). Ann Intern Med 115 (1991) 283-284
59. Bristol-Myers Squibb. Product information: Videx EC [didanosine] (March 2007), Bristol-Myers Squibb Company, Princeton (NJ)
60. Bristol-Myers Squibb. Product information: Zerit [stavudine] (July 2008), Bristol-Myers Squibb Company, Princeton (NJ)
61. Boehringer Ingelheim Pharmaceuticals. Product information: Viramune [nevirapine] (June 2008), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield (CT)
62. Boehringer Ingelheim Pharmaceuticals. Product information: Aptivus [tipranavir] (2008), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield (CT)
63. Hurst M., and Noble S. Stavudine: an update of its use in the treatment of HIV infection. Drugs 58 5 (1999) 919-949
64. Abbott Laboratories. Product information: Norvir [ritonavir] (May 2007), Abbott Laboratories, North Chicago
65. Jain M.K. Drug-induced liver injury associated with HIV medications. Clin Liver Dis 11 3 (2007) 615-639
66. Cooper C.L., Parbhakar M.A., and Angel J.B. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 34 9 (2002) 1259-1263
67. Piccinini M., Rinaudo M.T., Chiapello N., et al. The human 26S proteasome is a target of antiretroviral agents. AIDS 16 5 (2002) 693-700
68. Riddle T.M., Kuhel D.G., Woollett L.A., et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 276 40 (2001) 37514-37519 Epub 2001 Aug 23
69. King J., Wynn H., Brundage R., et al. Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharm 43 5 (2004) 291-310
70. Slain D., Pakyz A., Israel D., et al. Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 20 (2000) 898-907
71. Wen X., Wang J.S., Neuvonen P.J., and Backman J.T. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 57 (2002) 799-804
72. Maida I., Garcia-Gasco P., Sotgiu G., et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 13 1 (2008) 103-107
73. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129 (2005) 512-521
74. Chalasani N., Fontana R.J., Bonkovsky H.L., et al., Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 135 6 (2008) 1924-1934 1934.e1-4. Epub 2008 Sep 17
75. Garcia Rodriguez L.A., Stricker B.H., and Zimmerman H.J. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 156 (1996) 1327-1332
76. Mari J.Y., Guy C., Beyens M.N., et al. [Delayed drug-induced hepatic injury. Evoking the role of amoxicillin-clavulinic acid combination]. Therapie 55 (2000) 699-704
77. O'Donohue J., Oien K.A., Donaldson P., et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47 (2000) 717-720
78. Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects-review of the literature. Eur J Med Res 6 (2001) 139-149
79. Hautekeete M.L., Horsmans Y., Van Waeyenberge C., et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 117 (1999) 1181-1186
80. Bolzan H., Spatola J., Castelletto R., et al. [Intrahepatic cholestasis induced by amoxicillin alone]. Gastroenterol Hepatol 23 (2000) 237-239
81. Beard K., Belic L., Aselton P., et al. Outpatient drug-induced parenchymal liver disease requiring hospitalization. J Clin Pharmacol 26 (1986) 633-637
82. Wilson F.M., Belamaric J., Lauter C.B., et al. Anicteric carbenicillin hepatitis. Eight episodes in four patients. JAMA 232 (1975) 818-821
83. Goldstein L.I., Granoff M., and Waisman J. Hepatic injury due to oxacillin administration. Am J Gastroenterol 70 (1978) 171-174
84. Pollock A.A., Berger S.A., Simberkoff M.S., et al. Hepatitis associated with high-dose oxacillin therapy. Arch Intern Med 138 (1978) 915-917
85. De Valle M.B., Av Klinteberg V., Alem N., et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 24 (2006) 1187-1195
86. Davies M.H., Harrison R.F., Elias E., et al. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol 20 (1994) 112-116
87. Eggleston S.M., and Belandres M.M. Jaundice associated with cephalosporin therapy. Drug Intell Clin Pharm 19 (1985) 553-555
88. Ammann R., Neftel K., Hardmeier T., et al. Cephalosporin-induced cholestatic jaundice. Lancet 2 (1982) 336-337
89. Horn S., Aglas F., and Horina J.H. Cholestasis and liver cell damage due to hypersensitivity to erythromycin stearate - recurrence following therapy with erythromycin succinate. Wien Klin Wochenschr 111 (1999) 76-77
90. Keeffe E.B., Reis T.C., and Berland J.E. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate. Dig Dis Sci 27 (1982) 701-704
91. Derby L.E., Jick H., Henry D.A., et al. Erythromycin-associated cholestatic hepatitis. Med J Aust 158 (1993) 600-602
92. Braun P. Hepatotoxicity of erythromycin. J Infect Dis 119 (1969) 300-306
93. Ball P., Mandell L., Niki Y., et al. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 21 (1999) 407-421
94. Villeneuve J.P., Davies C., and Cote J. Suspected ciprofloxacin-induced hepatotoxicity. Ann Pharmacother 29 (1995) 257-259
95. Grassmick B.K., Lehr V.T., and Sundareson A.S. Fulminant hepatic failure possibly related to ciprofloxacin. Ann Pharmacother 26 (1992) 636-639
96. Chen H.J., Bloch K.J., and Maclean J.A. Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med 342 (2000) 359-360
97. Lucena M.I., Andrade R.J., Rodrigo L., et al. Trovafloxacin-induced acute hepatitis. Clin Infect Dis 30 (2000) 400-401
98. Dowling H.F., and Lepper M.H. Hepatic reactions to tetracycline. JAMA 188 (1964) 307-309
99. Whalley P.J., Adams R.H., and Combes B. Tetracycline toxicity in pregnancy. Liver and pancreatic dysfunction. JAMA 189 (1964) 357-362
100. Lawrenson R.A., Seaman H.E., Sundstrom A., et al. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf 23 (2000) 333-349
101. Bhat G., Jordan Jr. J., Sokalski S., et al. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol 27 (1998) 74-75
102. Gordin F.M., Simon G.L., Wofsy C.B., et al. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 100 (1984) 495-499
103. Rieder M.J. Mechanisms of unpredictable adverse drug reactions. Drug Saf 11 (1994) 196-212
104. Fries J., and Siragenian R. Sulfonamide hepatitis. Report of a case due to sulfamethoxazole and sulfisoxazole. N Engl J Med 274 (1966) 95-97
105. Young T.L., Achkar E., Tuthill R., et al. Chronic active hepatitis induced by nitrofurantoin. Cleve Clin Q 52 (1985) 253-256
106. Berry W.R., Warren G.H., and Reichen J. Nitrofurantoin-induced cholestatic hepatitis from cow's milk in a teenaged boy. West J Med 140 (1984) 278-280
107. Sharp J.R., Ishak K.G., and Zimmerman H.J. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 92 (1980) 14-19
108. Strohscheer H., and Wegener H.H. [Nitrofurantoin-induced granulomatous hepatitis]. MMW Munch Med Wochenschr 119 (1977) 1535-1536
109. Stricker B.H., Blok A.P., Claas F.H., et al. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 8 (1988) 599-606
110. Kelly B.D., Heneghan M.A., Bennani F., et al. Nitrofurantoin-induced hepatotoxicity mediated by CD8+ T cells. Am J Gastroenterol 93 (1998) 819-821
111. Engel J.J., Vogt T.R., and Wilson D.E. Cholestatic hepatitis after administration of furan derivatives. Arch Intern Med 135 (1975) 733-735
112. Franks A.L., Binkin N.J., Snider Jr. D.E., et al. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 104 (1989) 151-155
113. Polson J.E. Hepatotoxicity due to antibiotics. Clin Liver Dis 11 3 (2007) 549-561
114. Senior J.R. Drug hepatotoxicity from a regulatory perspective. Clin Liver Dis 11 3 (2007) 507-524
115. Steele M., Burk R., and DesPrez R. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 99 (1991) 465-471
116. Lehmann J., McKee D., Watson M.A., et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102 (1998) 1016-1023
117. Dickinson D.S., Bailey W.C., Hirschowitz B.I., et al. Risk factors for isoniazid (NIH)-induced liver dysfunction. J Clin Gastroenterol 3 (1981) 271-279
118. Huang Y.-S., Chern H.-D., Su W.-J., et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35 (2002) 883-889
119. Saukkonen J.J., Cohn D.L., Jasmer R.M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174 (2006) 935-952
120. Masubuchi Y., Sugiyama S., and Horie T. Th1/Th2 cytokine balance as a determinant of acetaminophen-induced liver injury. Chem Biol Interact (2008) [Epub ahead of print]
121. James L.P., Capparelli E.V., Simpson P.M., et al., Network of Pediatric Pharmacology Research Units, National Institutes of Child Health and Human Development. Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. Clin Pharmacol Ther 84 6 (2008) 684-690
122. Watkins P.B., Kaplowitz N., Slattery J.T., et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 296 1 (2006) 87-93
123. Copple I.M., Goldring C.E., Kitteringham N.R., et al. The Nrf2-Keap1 defence pathway: role in protection against drug-induced toxicity. Toxicology 246 1 (2008) 24-33 Epub 2007 Nov 12
124. McClain C.J., Price S., Barve S., et al. Acetaminophen hepatotoxicity: an update. Curr Gastroenterol Rep 1 1 (1999) 42-49
125. McClain C.J., Dryden G., and Krueger K. Complementary and alternative medicine in gastroenterology. In: Yamada T. (Ed). Textbook of gastroenterology. 5th edition (2008), Wiley-Blackwell 2844-2859
126. Angell M., and Kassirer J.P. Alternative medicine-the risks of untested and unregulated remedies. N Engl J Med 339 12 (1998) 839-841
127. Shaw D., Leon C., Koley S., et al. Traditional remedies and food supplements. A 5-year toxicological study (1991-1995). Drug Saf 17 5 (1997) 342-356
128. Cui J., Garle M., Eneroin P., et al. What do commercial ginseng preparations contain?. Lancet 344 (1994) 134
129. Ko R.J. Adulterants in Asian patent medicines. N Engl J Med 339 (1998) 847
130. Beigel Y., Ostfeld I., and Schoenfeld N. Clinical problem-solving. A leading question. N Engl J Med 339 12 (1998) 827-830
131. Schuppan D., Jia J.D., Brinkhavs R., et al. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 30 4 (1999) 1099-1104
132. Kaplowitz N. Hepatotoxicity of herbal remedies: insights into the intricacies of plant-animal warfare and cell death. Gastroenterology 113 4 (1997) 1408-1412
133. Lekehal M., Pessayre D., Lereau J.M., et al. Hepatotoxicity of the herbal medicine germander: metabolic activation of its furano diterpenoids by cytochrome P450 3A depletes cytoskeleton-associated protein thiols and forms plasma membrane blebs in rat hepatocytes. Hepatology 24 1 (1996) 212-218
134. Hanje A.J., Fortune B., Song M., et al. The use of selected nutritional supplements and complementary and alternative medicine in liver disease. Nutr Clin Pract 21 (2006) 255-272
135. Estes J.D., Stolpman D., Olyaei A., et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 138 (2003) 852-858
136. Ruschitzka F., Meier P.J., Turina M., et al. Acute heart transplant rejection due to Saint John's wort. Lancet 355 9203 (2000) 548-549
137. Piscitelli S.C., Burstein A.H., Chaitt D., et al. Indinavir concentrations and St. John's wort. Lancet 355 9203 (2000) 547-548